2-氯-6-甲基氨基吡嗪 | 848366-38-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯-6-甲基氨基吡嗪
• 中文别名: (6-氯吡嗪-2-基)-甲胺；(6-氯吡嗪-2-基)-乙胺；6-氯-n-甲基-2-吡嗪胺；2-氯-6-甲胺基吡嗪
• 英文名称: 6-chloro-N-methylpyrazin-2-amine
• 英文别名: 2-chloro-6-methylaminopyrazine
• CAS: 848366-38-1
• 化学式: C₅H₆ClN₃
• 分子量: 143.576
• InChiKey: PGGYLQQGCOJVSS-UHFFFAOYSA-N

物化性质

• 沸点：
  250.4±35.0 °C(Predicted)
• 密度：
  1.338±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-6-methylaminopyrazine
Synonyms: 6-Chloro-N-methylpyrazin-2-amine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-6-methylaminopyrazine
CAS number: 848366-38-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H6ClN3
Molecular weight: 143.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-6-甲基氨基吡嗪 在 过氧化双月桂酰 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 11.0h， 生成 diethyl 2-(1,3-diacetyl-5-(3-chloro-6-((1,3-dioxoisoindolin-2-yl)methyl)-5-(methylamino)pyrazin-2-yl)-2-oxoimidazolidin-4-yl)malonate
  参考文献：
  名称：

  黄药介导的吡嗪分子间烷基化

  摘要：

  报道了通过黄药的自由基化学对吡嗪和其他杂芳烃进行分子间CH官能化的简便方法。在这些杂芳烃上并入大量官能烷基的产率高并且区域选择性好至极好，从而导致高度官能化的杂芳族化合物。

  DOI：

  10.1016/j.tet.2018.08.040
• 作为产物：
  描述：

  2,6-二氯吡嗪 、 甲胺 以 乙醇 为溶剂， 反应 0.5h， 以88%的产率得到2-氯-6-甲基氨基吡嗪
  参考文献：
  名称：

  黄药介导的吡嗪分子间烷基化

  摘要：

  报道了通过黄药的自由基化学对吡嗪和其他杂芳烃进行分子间CH官能化的简便方法。在这些杂芳烃上并入大量官能烷基的产率高并且区域选择性好至极好，从而导致高度官能化的杂芳族化合物。

  DOI：

  10.1016/j.tet.2018.08.040

文献信息

• A Direct Approach to Orthogonally Protected α-Amino Aldehydes
  作者：Richard Lamb、Vincent L. Revil-Baudard、Samir Z. Zard

  DOI：10.1021/acs.orglett.9b02237

  日期：2019.8.16

  O-Neopentyl-xanthate 19 bearing a masked α-amino aldehyde, with the two functional groups orthogonally protected, reacts cleanly with many functional alkenes. The radical addition–transfer furnishes densely functionalized adducts that can be further transformed into an array of amino-substituted carbocycles and heteroaromatics. They are also easily converted into imidazolones.

  带有被掩蔽的α-氨基醛的O-新戊基黄原酸酯19，具有两个被正交保护的官能团，可以与许多官能烯烃干净地反应。自由基加成转移提供了高密度官能化的加合物，可以将其进一步转化为一系列氨基取代的碳环和杂芳族化合物。它们也容易转化为咪唑啉酮。
• Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
  作者：Allyn T. Londregan、Liuqing Wei、Jun Xiao、Nathanael G. Lintner、Donna Petersen、Robert G. Dullea、Kim F. McClure、Michael W. Bolt、Joseph S. Warmus、Steven B. Coffey、Chris Limberakis、Julien Genovino、Benjamin A. Thuma、Kevin D. Hesp、Gary E. Aspnes、Benjamin Reidich、Christopher T. Salatto、Jeffrey R. Chabot、Jamie H. D. Cate、Spiros Liras、David W. Piotrowski

  DOI：10.1021/acs.jmedchem.8b00650

  日期：2018.7.12

  The optimization of a new class of small molecule PCSK9 mRNA translation inhibitors is described. The potency, physicochemical properties, and off-target pharmacology associated with the hit compound (1) were improved by changes to two regions of the molecule. The last step in the synthesis of the congested amide center was enabled by three different routes. Subtle structural changes yielded significant

  描述了新型小分子PCSK9 mRNA翻译抑制剂的优化。通过改变分子的两个区域，与命中化合物（1）相关的效力，理化性质和脱靶药理作用得到改善。拥挤的酰胺中心合成的最后一步是通过三种不同的途径实现的。细微的结构变化导致药理学和脱靶范围的显着变化。这些努力导致鉴定具有适合体内评估的总体概况的7l和7n。在一项为期14天的毒理学研究中，7l的安全性优于铅7f。我们假设改善的安全性与7l与非翻译核糖体的结合减少以及由于7l脱靶蛋白质的低强度导致的转录选择性的明显改善有关。
• [EN] DIACYLGLYCEROL KINASE MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULANT LA DIACYLGLYCÉROL KINASE
  申请人：CARNA BIOSCIENCES INC

  公开号：WO2021130638A1

  公开（公告）日：2021-07-01

  The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

  本公开提供了调节二酰基甘油激酶的化合物以及用于治疗癌症（包括实体瘤）和病毒感染（如HIV或乙型肝炎病毒感染）的药物组合物。这些化合物可以单独使用或与其他药物联合使用。
• [EN] SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF<br/>[FR] COMPOSÉS CONTENANT DES SPIROCYCLIQUES ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：PHARMASCIENCE INC

  公开号：WO2018032104A1

  公开（公告）日：2018-02-22

  The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.

  本发明涉及一种新型的共价激酶抑制剂家族，该类化合物已发现对TEC激酶家族的成员，特别是ITK和/或TXK，BTK，TEC和/或其组合具有抑制活性。本发明涉及一种具有I式结构的化合物或其药学上可接受的盐、溶剂、盐的溶剂体、立体异构体、互变异构体、同位素、前药、复合物或其生物活性代谢物，用于治疗。
• Substituted heterocyclic compounds and methods of use
  申请人：Andersen Lyn Denise

  公开号：US20060069110A1

  公开（公告）日：2006-03-30

  The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

  本发明涉及吡啶、嘧啶及其衍生物，以及其药用盐。还包括一种治疗炎症、类风湿关节炎、帕盖特病、骨质疏松症、多发性骨髓瘤、葡萄膜炎、急性或慢性骨髓性白血病、胰岛素β细胞破坏、骨关节炎、类风湿脊柱炎、痛风性关节炎、炎症性肠病、成人呼吸窘迫综合征（ARDS）、牛皮癣、克罗恩病、过敏性鼻炎、溃疡性结肠炎、过敏反应、接触性皮炎、哮喘、肌肉退化、虚弱、赖特氏综合征、I型糖尿病、II型糖尿病、骨吸收性疾病、移植物抗宿主反应、阿尔茨海默病、中风、心肌梗塞、缺血再灌注损伤、动脉粥样硬化、脑外伤、多发性硬化、脑疟疾、败血症、脓毒性休克、中毒性休克综合征、发热、由HIV-1、HIV-2、HIV-3、巨细胞病毒（CMV）、流感病毒、腺病毒、疱疹病毒或带状疱疹感染引起的肌肉疼痛的方法，包括向哺乳动物施用上述化合物的有效量。